Skip to main content

Advertisement

SpringerLink
Log in

HIV Testing Updates and Challenges: When Regulatory Caution and Public Health Imperatives Collide

  • The Science of Prevention (JD Stekler, Section Editor)
  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Numerous improvements in HIV testing technology led recently to the first revision of recommendations for diagnostic laboratory testing in the USA in 25 years. Developments in HIV testing continue to produce tests that identify HIV infection earlier with faster turnaround times for test results. These play an important role in identifying HIV infection during the highly infectious acute phase, which has implication for both patient management and public health interventions to control the spread of HIV. Access to these developments, however, is often delayed by the regulatory apparatus for approval and oversight of HIV testing in the USA. This article summarizes recent developments in HIV diagnostic testing technology, outlines their implications for clinical management and public health, describes current systems of regulatory oversight for HIV testing in the USA, and proposes alternatives that could expedite access to improved tests as they become available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Centers for Disease Control and Prevention, Association of Public Health Laboratories. Laboratory testing for the diagnosis of HIV infection: updated recommendations. 2014:1-66. http://stacks.cdc.gov/view/cdc/23447. Accessed 09/20/2014. A comprehensive summary of HIV diagnostic testing technology and evidence for recommendations for the updated laboratory testing algorithm.

  2. Centers for Disease Control and Prevention. Notice to readers: approval of a new rapid test for HIV antibody. MMWR Morb Mortal Wkly Rep. 2002;51:1051–2.

    Google Scholar 

  3. O’Rourke M, Branson B, del Rio C, Larrabee S, Sax PE. Rapid fingerstick testing: a new era in HIV diagnostics. AIDS Clin Care. 2003;15:19–23,30.

    PubMed  Google Scholar 

  4. Hutchinson AB, Branson BM, Kim A, Farnham PG. A meta-analysis of the effectiveness of alternative HIV counseling and testing methods to increase knowledge of HIV status. AIDS. 2006;20:1597–604.

    Article  PubMed  Google Scholar 

  5. CDC. Protocols for confirmation of rapid HIV tests. MMWR Morb Mortal Wkly Rep. 2004;53:221–2.

    Google Scholar 

  6. Shah D, Chang C, Cheng K, Wachter A, Stewart J. Combined HIV antigen and antibody assay on a fully automated chemiluminescence based analyzer. 11th International Symposium on Bioluminescence and Chemiluminescence. Pacific Grove, CA: World Scientific Publishing Co. Pte. Ltd.; 2000:365-368.

  7. Ortho Diagnostics. VITROS Immunodiagnostic Products, Anti-HIV 1+2 Reagent Pack [product insert]. 2008. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm092018.pdf. Accessed July 14, 2013.

  8. Siemens Healthcare. HIV 1/O/2 Enhanced (EHIV) [product insert]. 2006; http://www.fda.gov/downloads/Biologicsbloodvaccines/Bloodbloodproducts/Approvedproducts/PremarketApprovalsPMAs/UCM091286.pdf. Accessed July 12, 2013.

  9. Abbott. Architect HIV Ag/Ab Combo [product insert]. 2010; http://www.abbottdiagnostics.com/Support/Technical_Library/Package_Inserts/getPIFile.cfm?controlNumber=345589. Accessed April 23, 2012.

  10. Bio-Rad. GS HIV Combo Ag/Ab EIA [product insert]. 2011; http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/UCM266211.pdf. Accessed April 23, 2012.

  11. Salmona M, Delarue S, Delaugerre C, Simon F, Maylin S. Clinical evaluation of BioPlex 2200 HIV Ag-Ab, an automated screening method providing discrete detection of HIV-1 p24 antigen, HIV-1 antibody, and HIV-2 antibody. J Clin Microbiol. 2014;52:103–7.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Branson BM. Rapid tests for HIV antibody. AIDS Rev. 2000; 76-83.

  13. Owen SM, Yang C, Spira T, et al. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol. 2008;46:1588–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol. 2011;52 Suppl 1:S17–22. Summarizes a comparison of the seroconversion sensitivity of FDA-approved HIV diagnostic tests and provides an example of a head-to-head comparison of different assays on the same challenge panel of specimens.

    Article  PubMed  Google Scholar 

  15. Alere Inc. Alere Determine HIV 1/2 Ag/Ab Combo [product insert]. 2013; http://www.alere.com/content/alere/us/en/product-details/determine-1-2-ag-ab-combo-us.html.html. Accessed October 30, 2014.

  16. Chembio Diagnostic Systems Inc. DPP HIV 1/2 Assay [product insert]. 2012; http://chembio.com/wp-content/uploads/2013/04/10-6273-0-Product-Insert-DPP-HIV-Rev-8.pdf. Accessed October 15, 2014.

  17. Food and Drug Administration (FDA). October 24, 2014 Approval Letter - Geenius HIV 1/2 Supplemental Assay 2014; http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm420751.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Accessed November 1, 2014.

  18. Delaney KP, Branson BM, Uniyal A, et al. Performance of an oral fluid rapid HIV 1/2 test: experience from four CDC studies. AIDS. 2006;20:1655–60.

    Article  PubMed  Google Scholar 

  19. Centers for Disease Control and Prevention. False-positive oral fluid rapid HIV tests--New York City, 2005-2008. MMWR Morb Mortal Wkly Rep. 2008;57:660–5.

    Google Scholar 

  20. O’Connell RJ, Merritt TM, Malia JA, et al. Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol. 2003;41:2153–5.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Stekler JD, O’Neal JD, Lane A, et al. Relative accuracy of serum, whole blood, and oral fluid HIV tests among Seattle men who have sex with men. J ClinVirol. 2013;58 Suppl 1:e19–22. Prospective clinical study among a frequently tested population with high HIV incidence comparing the accuracy of different HIV tests when performed on different types of specimens.

    Google Scholar 

  22. Stekler JD, Swenson PD, Coombs RW, et al. HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis. 2009;49:444–53.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Luo W, Masciotra S, Delaney KP, et al. Comparison of HIV oral fluid and plasma antibody results during early infection in a longitudinal Nigerian cohort. J Clin Virol. 2013;58 Suppl 1:e113–118. Study comparing sensitivity of oral fluid and serum specimens that were prospectively collected at frequent interval from recent seroconverters.

    Article  CAS  PubMed  Google Scholar 

  24. Gen-Probe. Aptima® HIV-1 RNA qualitative assay [product insert]. . 2009; http://www.gen-probe.com/pdfs/pi/501623RevA.pdf. Accessed February 4, 2011.

  25. Ritchie AV, Ushiro-Lumb I, Edemaga D, et al. SAMBA HIV semiquantitative test, a new point-of-care viral-load-monitoring assay for resource-limited settings. J Clin Microbiol. 2014;52:3377–83.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Tanriverdi S, Chen L, Chen S. A rapid and automated sample-to-result HIV load test for near-patient application. J Infect Dis. 2010;201 Suppl 1:S52–58.

    Article  CAS  PubMed  Google Scholar 

  27. Cohen MS, Dye C, Fraser C, Miller WC, Powers KA, Williams BG. HIV treatment as prevention: debate and commentary—will early infection compromise treatment-as-prevention strategies? PLoS Med. 2012;9:e1001232.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. J Infect Dis. 2010;202 Suppl 2:S270–277.

    Article  PubMed  Google Scholar 

  29. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med. 2011;364:1943–54. Summary article describing pathogenesis during acute HIV-1 infection and its importance for the subsequent clinical course of HIV disease and implications for enhanced HIV transmission.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Pilcher CD, Tien HC, Eron JJ, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004;189:1785–92.

    Article  PubMed  Google Scholar 

  31. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis. 2006;194:725–33.

    Article  PubMed  Google Scholar 

  32. Hamlyn E, Jones V, Porter K, Fidler S. Antiretroviral treatment of primary HIV infection to reduce onward transmission. Curr Opin HIV AIDS. 2010;5:283–90.

    Article  PubMed  Google Scholar 

  33. Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. 2012;205:87–96.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2013. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 10, 2013.

  35. Hocqueloux L, Saez-Cirion A, Rouzioux C. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. JAMA Intern Med. 2013;173:475–6.

    Article  PubMed  Google Scholar 

  36. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9:e1003211.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Smith MK, Rutstein SE, Powers KA, et al. The detection and management of early HIV infection: a clinical and public health emergency. J Acquir Immune Defic Syndr. 2013;63 Suppl 2:S187–199.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Pilcher CD, Joaki G, Hoffman IF, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS. 2007;21:1723–30.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198:687–93.

    Article  PubMed  Google Scholar 

  40. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis. 2007;195:951–9.

    Article  CAS  PubMed  Google Scholar 

  41. Pilcher CD, Christopoulos KA, Golden M. Public health rationale for rapid nucleic acid or p24 antigen tests for HIV. J Infect Dis. 2010;201 Suppl 1:S7–15.

    Article  CAS  PubMed  Google Scholar 

  42. Centers for Disease Control (CDC). Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb Mortal Wkly Rep. 1989;38:1–7.

    Google Scholar 

  43. Centers for Disease Control and Prevention (CDC). Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm—United States, 2011-2013. MMWR Morb Mortal Wkly Rep. 2013;62:489–94. Description of two evaluation of the updated HIV testing recommendations demonstrating the ability to detect acute HIV-1 infections and the high viral load observed in acute-stage patients.

    Google Scholar 

  44. Eshleman SH, Khaki L, Laeyendecker O, et al. Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab combo assay. J Acquir Immune Defic Syndr. 2009;52:121–4.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Linley L, Ethridge SF, Oraka E, et al. Evaluation of supplemental testing with the Multispot HIV-1/HIV-2 rapid test and APTIMA HIV-1 RNA qualitative assay to resolve specimens with indeterminate or negative HIV-1 Western blots. J Clin Virol. 2013;58 Suppl 1:e108–112.

    Article  CAS  PubMed  Google Scholar 

  46. New York Department of Health and Mental Hygiene. 2012 HEALTH ADVISORY #29: missed opportunity to detect acute HIV infection. 2012. http://www.nyc.gov/html/doh/downloads/pdf/cd/2012/12md29.pdf. Accessed 3/29/2013.

  47. Pandori MW, Hackett Jr J, Louie B, et al. Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J Clin Microbiol. 2009;47:2639–42.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Patel P, Mackellar D, Simmons P, et al. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Arch Intern Med. 2010;170:66–74.

    Article  CAS  PubMed  Google Scholar 

  49. Pilcher CD, Louie B, Facente S, et al. Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco. PLoS One. 2013;8:e80629.

    Article  PubMed Central  PubMed  Google Scholar 

  50. CDC. HIV-2 infection surveillance—United States, 1987-2009. MMWR Morb Mortal Wkly Rep. 2011;60:985–8.

    Google Scholar 

  51. Torian LV, Eavey JJ, Punsalang AP, et al. HIV type 2 in New York City, 2000-2008. Clin Infect Dis. 2010;51:1334–42.

    Article  PubMed  Google Scholar 

  52. Nasrullah M, Ethridge SF, Delaney KP, et al. Comparison of alternative interpretive criteria for the HIV-1 Western blot and results of the Multispot HIV-1/HIV-2 rapid test for classifying HIV-1 and HIV-2 infections. J Clin Virol. 2011;52 Suppl 1:S23–27.

    Article  PubMed  Google Scholar 

  53. Ntemgwa ML, d’Aquin TT, Brenner BG, RJ C, Wainberg MA. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother. 2009;53:3611–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Hizi A, Tal R, Shaharabany M, et al. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob Agents Chemother. 1993;37:1037–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Westheimer E, Fu J, Radix A, et al. An HIV-1 RNA test following a reactive fourth-generation antigen/antibody combination assay confirms a high proportion of HIV infections. J ClinVirol. 2014. http://www.journalofclinicalvirology.com/article/S1386-6532(14)00397-7/pdf. Accessed November 1, 2014. Comparison of the HIV-1 Western blot, Multispot HIV-1/HIV-2 Antibody Differentiation Assay, and APTIMA qualitative RNA assay for confirmation of HIV infection in prospectively collected specimens with a reactive combination antigen/antibody immunoassay.

  56. Ethridge SF, Wesolowski LG, Nasrullah M, et al. Comparative evaluation of Aptima HIV-1 Qualitative RNA assay performance using plasma and serum specimens from persons with established HIV-1 infection. J Clin Virol. 2011;52 Suppl 1:S63–66.

    Article  CAS  PubMed  Google Scholar 

  57. Ren A, Louie B, Rauch L, et al. Screening and confirmation of human immunodeficiency virus type 1 infection solely by detection of RNA. J Med Microbiol. 2008;57:1228–33.

    Article  PubMed  Google Scholar 

  58. Murphy G, Aitken C. HIV testing—the perspective from across the pond. J Clin Virol. 2011;52 Suppl 1:S71–76.

    Article  PubMed  Google Scholar 

  59. Jurriaans S, Back NK, Wolthers KC. Ten years of HIV testing with fourth generation assays: the Amsterdam experience. J Clin Virol. 2011;52 Suppl 1:S67–69.

    Article  PubMed  Google Scholar 

  60. CDC. Acute HIV infection—New York City, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:1296–9.

    Google Scholar 

  61. Mansfield E, O’Leary TJ, Gutman SI. Food and Drug Administration regulation of in vitro diagnostic devices. J Mol Diagn. 2005;7:2–7.

    Article  PubMed Central  PubMed  Google Scholar 

  62. Food and Drug Administration (FDA). Medical device user fees for fiscal year 2015 2014; http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/ucm407660.htm. Accessed December 3, 2014.

  63. Commission of the European Communities. Common technical specifications for in vitro diagnostic medical devices. 2009; http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2002D0364:20091201:EN:PDF. Accessed December 2, 2014.

  64. Food and Drug Administration (FDA). Transcript of the 59th Blood Products Advisory Committee meeting. 1998; www.fda.gov/ohrms/dockets/ac/98/transcpt/3431t1.rtf. Accessed December 2, 2014.

  65. Food and Drug Administration (FDA). Summary of safety and effectiveness, OraQuick In-Home HIV Tst. 2012; http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/UCM312534.pdf. Accessed November 20, 2014.

  66. Myers JE, El-Sadr WM, Zerbe A, Branson BM. Rapid HIV self-testing: long in coming but opportunities beckon. AIDS. 2013;27:1687–5.

    Article  PubMed  Google Scholar 

  67. Centers for Disease Control and Prevention (CDC). HIV surveillance report, 2012. 2014; http://www.cdc.gov/hiv/library/reports/surveillance/2012/surveillance_Report_vol_24.html. Accessed December 1, 2014.

  68. Busch MP, Courouce AM. Relative sensitivity of United States and European assays for screening blood donors for antibodies to human immunodeficiency viruses. Transfusion. 1997;37:352–4.

    Article  CAS  PubMed  Google Scholar 

  69. Code of Federal Regulations, Title 42. Vol 5, Section 493.15. Washington, DC 2013.

  70. Lusky K. Rapid HIV tests a weather vane for waived tests. CAP Today. 2004. http://www.captodayonline.com/Archives/feature_stories/0404RapidHIV.html. Accessed October 20, 2014

  71. Howerton D, Anderson N, Bosse D, Granade S, Westbrook G. Good laboratory practices for waived testing sites: survey findings from testing sites holding a certificate of waiver under the clinical laboratory improvement amendments of 1988 and recommendations for promoting quality testing. MMWR Recomm Rep. 2005;54:1–25.

    PubMed  Google Scholar 

  72. Food and Drug Administration (FDA). Guidance for industry and FDA staff: recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver applications for manufacturers of in vitro diagnostic devices. 2008. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070890.pdf. Accessed October 22, 2014.

  73. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17.

    PubMed  Google Scholar 

  74. Centers for Medicare and Medicaid Services (CMS). Standard: establishment and verification of performance specifications. 2008; 42 CFR 5 § 493.1253.

  75. Lilian RR, Bhowan K, Sherman GG. Early diagnosis of human immunodeficiency virus-1 infection in infants with the NucliSens EasyQ assay on dried blood spots. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2010;48:40–3.

    Article  CAS  Google Scholar 

  76. Parry JV, Mortimer PP, Nicoll AG. Performance assessment of neonatal dried blood spot testing for HIV antibody. Commun Dis Rep CDR Rev. 1992;2:R128–130.

    CAS  PubMed  Google Scholar 

  77. Smit PW, Sollis KA, Fiscus S, et al. Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS One. 2014;9:e86461.

    Article  PubMed Central  PubMed  Google Scholar 

  78. Sullivan TJ, Antonio-Gaddy MS, Richardson-Moore A, Styer LM, Bigelow-Saulsbery D, Parker MM. Expansion of HIV screening to non-clinical venues is aided by the use of dried blood spots for Western blot confirmation. J Clin Virol. 2013;58 Suppl 1:e123–126.

    Article  PubMed  Google Scholar 

  79. Cardenas AM, Baughan E, Hodinka RL. Evaluation of the Bio-Rad Multispot HIV-1/HIV-2 rapid test as an alternative to Western blot for confirmation of HIV infection. J Clin Virol. 2013;58 Suppl 1:e97–e103.

    Article  PubMed  Google Scholar 

  80. Pandori MW, Westheimer E, Gay C, et al. The Multispot rapid HIV-1/HIV-2 differentiation assay is comparable with the Western blot and an immunofluorescence assay at confirming HIV infection in a prospective study in three regions of the United States. J Clin Virol. 2013;58 Suppl 1:e92–96.

    Article  CAS  PubMed  Google Scholar 

  81. Ramos EM, Harb S, Dragavon J, Coombs RW. Clinical performance of the Multispot HIV-1/HIV-2 rapid test to correctly differentiate HIV-2 from HIV-1 infection in screening algorithms using third and fourth generation assays and to identify cross reactivity with the HIV-1 Western Blot. J Clin Virol. 2013;58 Suppl 1:e104–107.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  82. Styer LM, Sullivan TJ, Parker MM. Evaluation of an alternative supplemental testing strategy for HIV diagnosis by retrospective analysis of clinical HIV testing data. J Clin Virol. 2011;52 Suppl 1:S35–40.

    Article  PubMed  Google Scholar 

  83. Torian LV, Forgione LA, Punsalang AE, Pirillo RE, Oleszko WR. Comparison of Multispot EIA with Western blot for confirmatory serodiagnosis of HIV. J Clin Virol. 2011;52 Suppl 1:S41–44.

    Article  PubMed  Google Scholar 

  84. Food and Drug Administration (FDA). March 25, 2013 Supplement letter—Multispot HIV-1/HIV-2 rapid test. 2013; http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm357028.htm. Accessed August 30, 2013.

  85. Masciotra S, Luo W, Youngpairoj AS, et al. Performance of the Alere determine HIV-1/2 Ag/Ab combo rapid test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. J Clin Virol. 2013;58 Suppl 1:e54–58.

    Article  CAS  PubMed  Google Scholar 

  86. Malloch L, Kadivar K, Putz J, et al. Comparative evaluation of the Bio-Rad Geenius HIV-1/2 confirmatory assay and the Bio-Rad Multispot HIV-1/2 rapid test as an alternative differentiation assay for CLSI M53 algorithm I. J Clin Virol. 2013;58 Suppl 1:e85–91.

    Article  CAS  PubMed  Google Scholar 

  87. Montesinos I, Eykmans J, Delforge ML. Evaluation of the Bio-Rad Geenius HIV-1/2 test as a confirmatory assay. J Clin Virol. 2014;60:399–401.

    Article  CAS  PubMed  Google Scholar 

  88. Hsu J, Brozek JL, Terracciano L, et al. Application of GRADE: making evidence-based recommendations about diagnostic tests in clinical practice guidelines. Implement Sci. 2011;6:62.

    Article  PubMed Central  PubMed  Google Scholar 

  89. Ly TD, Ebel A, Faucher V, Fihman V, Laperche S. Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? J Virol Methods. 2007;143:86–94.

    Article  CAS  PubMed  Google Scholar 

  90. Laperche S, Leballais L, Ly TD, Plantier JC. Failures in the detection of HIV p24 antigen with the determine HIV-1/2 Ag/Ab combo rapid test. J Infect Dis. 2012;206:1946–7. author reply 1949-1950.

    Article  PubMed  Google Scholar 

  91. Laperche S, Morel P, Deschaseaux M, et al. HIV antibody screening remains indispensable for ensuring viral safety of blood components despite NAT implementation. Transfusion. 2003;43:1428–32.

    Article  PubMed  Google Scholar 

  92. Food and Drug Administration (FDA). FDA proposes lower risk classification for certain tuberculosis tests. 2012; http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm296308.htm. Accessed December 12, 2014.

  93. Branson BM. Home sample collection tests for HIV infection. JAMA. 1998;280:1699–701.

    Article  CAS  PubMed  Google Scholar 

  94. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med. 1997;102(5B):117–24.

    Article  CAS  PubMed  Google Scholar 

  95. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871–9.

    Article  PubMed  Google Scholar 

Download references

Compliance With Ethics Guidelines

ᅟ

Conflict of Interest

Bernard M. Branson declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Scientific Affairs LLC, Eldorado Drive NE, Atlanta, GA, 30345, USA

    Bernard M. Branson

Authors
  1. Bernard M. Branson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernard M. Branson.

Additional information

This article is part of the Topical Collection on The Science of Prevention

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Branson, B.M. HIV Testing Updates and Challenges: When Regulatory Caution and Public Health Imperatives Collide. Curr HIV/AIDS Rep 12, 117–126 (2015). https://doi.org/10.1007/s11904-014-0251-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-014-0251-7

Keywords

Search

Navigation